Article

Researchers Explore New T-Cell Therapy Method

Treatment shows promise in fighting lymphoma in early studies.

A new approach has been created with the potential to simultaneously speed up and improve the process of T-cell therapy, according to a recent study.

The study was conducted by researchers at the Fred Hutchinson Cancer Research Center and published in Nature Biotechnology.

T-cell therapy is a form of immunotherapy that uses a patient’s own T-cells that are engineered to carry new proteins that can attack cancer.

In the study, researchers used a special, small protein tag that could purify and track T-cells after they were engineered. This new approach was performed to examine its effects on a mouse model of lymphoma and on human cancerous cells in the laboratory.

Researchers believe that this new approach could improve current T-cell therapy methods by boosting the potency of cells; growing larger numbers of cancer fighting T-cells; adding a potential “kill switch” that can deactivate cells quickly in the event of toxic side effects; and cutting down the amount of time for immune cell processing from 14 to 20 days to 9 days or less.

Related Videos
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com
Child with cancer -- Image credit: Alexis Scholtz/peopleimages.com | stock.adobe.com
Image Credit: © Rawpixel.com - stock.adobe.com
Image Credit: © RandyJay - stock.adobe.com
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC